Lafutidine

{{Drugbox | Verifiedfields = changed | Watchedfields = changed | verifiedrevid = 443919033 | IUPAC_name = 2-[(2-furylmethyl)sulfinyl]-N-((2Z)-4-{[4-(piperidin-1-ylmethyl)pyridin-2-yl]oxy}but-2-en-1-yl)acetamide | image = Lafutidine.png | width = 250

| tradename = | Drugs.com = International Drug Names | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = Oral

| bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =

| CAS_number_Ref =  ^Y | CAS_number = 118288-08-7 | ATC_prefix = A02 | ATC_suffix = BA08 | ATC_supplemental = | PubChem = 5282136 | DrugBank_Ref =  ^Y | DrugBank = | UNII_Ref =  ^Y | UNII = 49S4O7ADLC | KEGG_Ref =  ^Y | KEGG = D01131 | ChemSpiderID_Ref =  ^N | ChemSpiderID = 4445337

| chemical_formula = | C=22 | H=29 | N=3 | O=4 | S=1 | molecular_weight = 431.54 g/mol | smiles = C1CCN(CC1)CC2=CC(=NC=C2)OC/C=C\CNC(=O)C[S+](CC3=CC=CO3)[O-] | InChI = 1/C22H29N3O4S/c26-21(18-30(27)17-20-7-6-14-28-20)23-9-2-5-13-29-22-15-19(8-10-24-22)16-25-11-3-1-4-12-25/h2,5-8,10,14-15H,1,3-4,9,11-13,16-18H2,(H,23,26)/b5-2- | InChIKey = KMZQAVXSMUKBPD-DJWKRKHSBS | StdInChI_Ref =  ^N | StdInChI = 1S/C22H29N3O4S/c26-21(18-30(27)17-20-7-6-14-28-20)23-9-2-5-13-29-22-15-19(8-10-24-22)16-25-11-3-1-4-12-25/h2,5-8,10,14-15H,1,3-4,9,11-13,16-18H2,(H,23,26)/b5-2- | StdInChIKey_Ref =  ^N | StdInChIKey = KMZQAVXSMUKBPD-DJWKRKHSSA-N }}

WikiDoc Resources for Lafutidine
Articles
Most recent articles on Lafutidine Most cited articles on Lafutidine Review articles on Lafutidine Articles on Lafutidine in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Lafutidine Images of Lafutidine Photos of Lafutidine Podcasts & MP3s on Lafutidine Videos on Lafutidine
Evidence Based Medicine
Cochrane Collaboration on Lafutidine Bandolier on Lafutidine TRIP on Lafutidine
Clinical Trials
Ongoing Trials on Lafutidine at Clinical Trials.gov Trial results on Lafutidine Clinical Trials on Lafutidine at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Lafutidine NICE Guidance on Lafutidine NHS PRODIGY Guidance FDA on Lafutidine CDC on Lafutidine
Books
Books on Lafutidine
News
Lafutidine in the news Be alerted to news on Lafutidine News trends on Lafutidine
Commentary
Blogs on Lafutidine
Definitions
Definitions of Lafutidine
Patient Resources / Community
Patient resources on Lafutidine Discussion groups on Lafutidine Patient Handouts on Lafutidine Directions to Hospitals Treating Lafutidine Risk calculators and risk factors for Lafutidine
Healthcare Provider Resources
Symptoms of Lafutidine Causes & Risk Factors for Lafutidine Diagnostic studies for Lafutidine Treatment of Lafutidine
Continuing Medical Education (CME)
CME Programs on Lafutidine
International
Lafutidine en Espanol Lafutidine en Francais
Business
Lafutidine in the Marketplace Patents on Lafutidine
Experimental / Informatics
List of terms related to Lafutidine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Lafutidine (INN) is a second generation histamine H₂ receptor antagonist having multimodal mechanism of action and used to treat gastrointestinal disorders. It is marketed in Japan and India.

Medical use

Lafutidine is used to treat gastric ulcers, duodenal ulcers, stomal ulcers, wounds in the lining of the stomach associated with acute gastritis and with acute exacerbation of chronic gastritis.

Adverse effects

Adverse events observed during clinical trials included constipation, diarrhea, drug rash, nausea or vomiting and dizziness.

Mechanisms of action

Like other H2 receptor antagonists it prevents the secretion of gastric acid. It also activates calcitonin gene related peptide, resulting in the stimulation of nitric oxide (NO) and regulation of gastric mucosal blood flow, increases somatostatin levels also resulting in less gastric acid secretion, causes the stomach lining to generate more mucin, inhibits neutrophil activation thus preventing injury from inflammation, and blocks the attachment of H. pylori to gastric cells.

History

It is marketed in Japan as Stogar by UCB and in India as Lafaxid by Zuventus Healthcare.